Critical knowledge on how to run clinical trials is not formalized in textbooks or courses but is passed down through a slow apprenticeship model. This limits the spread of best practices and forces even highly educated scientists to "fly blind" when entering the industry, perpetuating inefficiencies.

Despite sound science, many recent drug launches are failing. The root cause is not the data but an underinvestment in market conditioning. Cautious investors and tighter budgets mean companies are starting their educational and scientific storytelling efforts too late, failing to prepare the market adequately.

Unlike the military, which restricts generals from immediately working for defense contractors, no such safeguards exist for executives moving between pharmaceutical companies and regulatory bodies like the FDA. This creates a perpetual 'revolving door' and significant conflicts of interest in public health.

By offering deep discounts exclusively through select telehealth platforms, drugmakers create a powerful sales channel that may incentivize providers to preferentially prescribe their products. This arrangement raises ethical concerns that financial incentives could override independent medical judgment, potentially compromising patient care.

As AI becomes more integrated into pharma, a need for validation will emerge. AI models used for medical affairs or commercial tasks will likely require accreditation from a neutral third party, similar to a 'certified pre-owned' car, to ensure reliability, compliance, and effectiveness.

Success in a CMC role requires more than deep scientific expertise. It demands an equally strong understanding of regulatory guidelines and the ability to interpret and navigate them like a lawyer. Serving both patients and health authorities means mastering both disciplines is essential for program success.

Early-career professionals should join large pharma companies to learn drug development correctly. These organizations provide the massive scale, resources, and established processes that smaller companies lack, offering an unparalleled educational foundation for a career in the industry.

Pharmaceutical companies invest in creating high-quality, patient-centric educational documents. However, these resources often fail to reach patients because physicians are hesitant to distribute materials bearing a corporate logo, creating a "last-mile" delivery problem for crucial information.

Successful drug launches require nailing three fundamentals. Common failures include: misjudging the patient population (epidemiology), failing to secure reimbursement and patient access, and lacking clear differentiation against the established "gold standard" treatment in physicians' minds.